Our laboratory is interested in the molecular control of normal and malignant stem cells with an emphasis on the hematopoietic system. Blood cells need to be continuously replenished by a small population of hematopoietic stem cells (HSCs) that have the capacity to both self-renew and mature stepwise into all known blood lineages. HSCs are also the ancestors of leukemia and lymphoma cells. As HSCs mature, they undergo successive changes in gene expression. The transcriptional apparatus must ensure that genes specific to immature cells are repressed as differentiation proceeds, while genes that are necessary for mature cells become activated. This activating and inactivating of genes is achieved by cooperative action of a variety of lineage-specific and general transcription factors and the complex molecular machinery that regulates the accessibility of different regions of the genome in chromatin. We investigate how transcription factors establish differentiation-specific transcriptional programs and how such programs can become derailed in cancer, leukemia and lymphoma.

Transcriptional control of normal and malignant hematopoietic stem cells in the adult bone marrow

Hematopoiesis in the bone marrow emanates HSCs. We are studying the basic biology of HSCs. Specifically we explore how a network of transcription factors that includes Tel-Etv6, Gfi1, Gfi1b and Gata2 maintains HSCs in the bone marrow (Hock et al. 2004, Genes & Development; Hock et al. 2004, Nature). The goal is to exploit the biology of transcriptional regulation of HSCs to maintain, expand, and possibly even generate HSCs ex vivo so that more patients will have the option of bone marrow transplantation. In a closely related effort, we are exploring the molecular programs of stem cells in leukemia and lymphoma to identify differences in their molecular regulation compared with normal HSCs. Such differences may allow us to specifically target tumor stem cells while sparing normal blood formation.
Dr. Hock’s laboratory works on molecular mechanisms of normal differentiation and malignant transformation. The image shows normal blood cells and leukemic cells (arrows) from a novel experimental model generated in the lab.

Deciphering the molecular events leading to acute lymphoblastic leukemia of childhood

About one in 2000 children develops this catastrophic illness, most often with a t(12;21) translocation. Despite very aggressive treatments, not all children can be cured, and some suffer from long-term side effects of their therapy. Rational development of more specific, less toxic treatments requires a precise understanding of the molecular mechanisms that cause the disease. We have discovered that TEL-AML1, the first hit in childhood leukemia, generates a preleukemic, latent lesion in HSCs. We are now exploring how additional genetic hits cooperate to derail normal blood development and generate leukemia. Deciphering the multistep pathogenesis of this entity is likely to serve as a paradigm for the development of other malignant diseases.

Exploration of novel epigenetic regulators in stem cells

Our understanding of how specialized cells of the body establish their identity by regulating access to genes continues to increase. For example, a large fraction of the genes active in brain cells are inactive in blood cells and, therefore, are stored in a very dense, inaccessible state. As most molecules involved in the regulation of gene accessibility have only recently been identified, studying their biology is likely to provide unique opportunities for the development of entirely novel therapies. We are investigating the utility of a group of proteins termed MBT-proteins, which is very important for condensing DNA and modifying histones. Evidence suggests that this protein family may play important roles in normal and malignant blood formation, but its precise functions remain poorly understood. Our laboratory has recently discovered an entirely novel, essential function of the family member L3mbtl2 in pluripotent stem cells.

Selected Publications:


* Corresponding authors